Stay updated with breaking news from Alexander Drilon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Foundation Expands its Research Reviewing Body to Meet Strategic Research Investment ObjectiveNEW YORK, June 27, 2022 /PRNewswire/ -- The Lung Can...
/PRNewswire/ -- The Hamoui Foundation and LUNGevity Foundation today announced the 2022 recipients of the first The Hamoui Foundation/LUNGevity Clinical...
Fatigue 17 3 12 2 Lipase increased 17 3 17 2 Anaemia 16 5 2 - Amylase increased 15 1 13 1 Nausea 12 1 7 - Vomiting 12 3 4 - Oedema peripheral 11 - 9 - Abdominal pain 10 2 1 -... | October 7, 2021
Share this article Share this article CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC), including NUV-520 – a potential best-in-class ROS1-selective inhibitor – and NUV-655 – an ALK-selective inhibitor. Data are being presented at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting from April 10-15 in two separate...
Crizotinib (Xalkori) has approval as first-line therapy for ROS1 fusion-positive metastatic NSCLC but has poor CNS penetration, the authors noted, adding that in about half of patients treated with crizotinib, initial progression occurs only in the CNS. Entrectinib is designed to cross the blood-brain barrier, and preclinical studies showed that the agent achieves high CNS concentrations, which were associated with strong efficacy in brain-tumor models. Integrated Analysis For the analysis, the investigators evaluated entrectinib in three phase I or II clinical trials of patients with locall...